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Abstract
PURPOSE: The objective is to validate the combination of 3′-deoxy-3′-[18F]fluorothymidine (18F-FLT) and
18F-fluorodeoxyglucose (18F-FDG) as a “novel” positron emission tomography (PET) tracer for better visualization of
cancer cell components in solid cancers than individual radiopharmaceutical. METHODS: Nude mice with sub-
cutaneous xenografts of human non–small cell lung cancer A549 and HTB177 cells and patients with lung cancer
were included. In ex vivo study, intratumoral radioactivity of 18F-FDG, 18F-FLT, and the cocktail of 18F-FDG and 18F-FLT
detected by autoradiography was compared with hypoxia (by pimonidazole) and proliferation (by bromodeoxyuridine)
in tumor section. In in vivo study, first, 18F-FDG PET and 18F-FLT PET were conducted in the same subjects (mice and
patients) 10 to 14 hours apart. Second, PET scan was also performed 1 hour after one tracer injection; subsequently,
the other was administered and followed the second PET scan in themouse. Finally, 18F-FDG and 18F-FLT cocktail PET
scan was also performed in the mouse. RESULTS:When injected individually, 18F-FDG highly accumulated in hypoxic
zones and high 18F-FLT in proliferative cancer cells. In case of cocktail injection, high radioactivity correlatedwith hypoxic
regions and highly proliferative and normoxic regions. PETdetected that intratumoral distribution of 18F-FDGand 18F-FLT
was generally mismatched in both rodents and patients. Combination of 18F-FLT and 18F-FDG appeared to map more
cancer tissue than single-tracer PET. CONCLUSIONS: Combination of 18F-FDG and 18F-FLT PET imaging would give a
more accurate representation of total viable tumor tissue than either tracer alone and would be a powerful imaging
strategy for cancer management.
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Introduction
Positron emission tomography (PET) imaging has emerged as an
important clinical tool for cancer detection, staging and monitoring the
response to therapy. 18F-fluorodeoxyglucose (18F-FDG) and 3′-Deoxy-
3′-[18F]fluorothymidine (18F-FLT) are the most commonly used
PET tracers for imaging tumor glucose metabolism and cell prolifera-
tion, respectively. Numerous studies in patients and in animal models
have been performed to identify which tracer is most optimal in cancer
management; however, results were mixed [1–12]. In these studies,
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although the individual tumor accumulations of each tracer were well
studied, investigators failed to fully understand the differences in intra-
tumoral distribution of each tracer.
Solid tumors have complex and highly heterogeneous micro-
environment, being composed of viable cancer cells, stroma, and
necrotic zones [13–15]. Viable cancer cells are usually either hypoxic
or oxic or either minimally or highly proliferative. Cellular prolifer-
ation and hypoxia are generally exclusive [16–18]. Although 18F-FDG
is often used as a surrogate for tumor tissue, recent in vivo [9,10,19] and
in vitro [8,20,21] studies demonstrated that this tracer preferentially
accumulates in hypoxic cancer cells. Conversely, 18F-fluorothymidine
accumulates mostly in proliferative cancer cells, which are usually not
hypoxic [19]. Therefore, 18F-FLT may fail to label or accurately iden-
tify minimally proliferative and hypoxic cancer cells that are present in
most solid cancers.
Noncancerous intratumoral stroma and necrotic zones accumulate
low levels of 18F-FDG and 18F-FLT. Therefore, low 18F-FDG uptake
of the oxic cancer cells and low 18F-fluorothymidine retention of the
hypoxic cancer cells are not distinguishable from stroma and necrosis
[19]. So, the presence of weak signal from either tracer alone is
ambiguous and does not necessarily represent the absence of viable
tumor tissue.
There are circumstances where it would be desirable to identify
the total tumor tissue burden without identifying the hypoxic and
proliferative cancer cell components individually. Obviously, neither
18F-FDG nor 18F-FLT has the ability to visualize all of the viable
cancer cells present in a tumor. However, their intratumoral comple-
mentary distribution patterns may be exploited if the two tracers are
given in combination. Recently, Lin and colleagues reported that
18F-FDG and 18F-NaF can be combined in a single PET/computed
tomography (CT) exam by administering the two radiopharma-
ceuticals simultaneously or in sequence on the same day. By doing
so, the combined PET/CT scan appeared to increase the sensitivity
of detection of osseous lesions compared to 18F-FDG–only PET/CT
scans [22], albeit this proposal has been argued [23].
We hypothesized that combined simultaneous 18F-FDG and
18F-FLT injection PET scan might encompass both hypoxic (non-
proliferative) and oxic (usually proliferative) cancer cells, hence,
visualize more cancer cells when compared to scans obtained by
each individual radiopharmaceutical injections. In this study, we
used human non–small cell lung cancer (NSCLC) HTB177 and
A549 cells grown as subcutaneous xenografts in nude mice as well
as patients with lung cancer to test our hypothesis. Subjects were
intravenously injected with 18F-FLT and 18F-FDG in combination in
sequence with a 10- to 14-hour interval or simultaneously as “cocktail.”
In animal studies, the proliferation marker bromodeoxyuridine (BrdU)
and the hypoxia marker pimonidazole were also injected intravenously
together. Intratumoral distribution of tracer radioactivity was related to
histologic findings of proliferation, hypoxia, perfusion, stroma, and
necrosis. Our ex vivo experiments on mice reconfirmed that neither
radiotracer alone could identify all of the viable tumor cells but that
the combination of both tracers more accurately identified viable
cancer cells in the tumors. The combined injection of these tracers
was also tested with PET scans in live subjects; this confirmed that
the combination of two radiopharmaceuticals visualizes more viable
cancer cells. On the basis of this proof-of-concept study, we con-
cluded that, compared to individual injection of either tracer, the
simultaneously combined IV injection of 18F-FDG and 18F-FLT
for PET studies is a novel imaging strategy and may noninvasively
achieve more complete and accurate identification of viable lung
cancer cells both in mice and humans.
Materials and Methods
Mouse Model of Lung Cancer
In mouse experiments, human NSCLC A549 and HTB177 cell
lines were used, which were purchased from American Type Culture
Collection (Manassas, VA). A549 and HTB177 cells were maintained
in F-12K Medium (American Type Culture Collection) and RPMI
1640 medium (Cellgro, Herndon, VA), respectively. All media were
supplementedwith 10%FBS (Gemini Bio-Products,West Sacramento,
CA), 1% glutamine, and 1% antibiotic mixture (Cellgro). Cells were
grown in a humidified incubator at 37°C air atmosphere contain-
ing 5% CO2. Exponentially growing cells were harvested using
0.25% (wt/vol) Trypsin–0.53-mM EDTA solution, and harvested cells
were washed and suspended in phosphate-buffered saline. The number
of viable cells was counted using a Vi-CELL cell viability analyzer
(Beckman Coulter, Miami, FL).
All experiments were performed on 6-week-old female athymic
NCr-nu/nu mice purchased from National Cancer Institute (NCI)-
Frederick Cancer Research Institute (Bethesda, MD). Nude mice
were maintained and used according to the guidelines of University
of Louisville Health Center Animal Care and Use Committee. The
animal study proposal had been approved by the Committee. Animals
were housed five per cage and kept in the institutional small animal
facility at a controlled constant temperature and humidity. Food pellets
and water were provided ad libitum.
Human Studies
The Institutional Review Board of Inner Mongolia Medical Uni-
versity as well as the local ethics committee approved this investiga-
tion. Written consent was obtained from patients. The Institutional
Review Board of University of Louisville has approved data transfer
and use. Two patients with biopsy-proven pretreated lung adeno-
carcinoma were approved to include in the proof-of-concept study.
Study Design and Experiment Procedures
In ex vivo mouse studies, to relate the accumulation of 18F-FDG,
18F-FLT, and the cocktail 18F-FDG and 18F-FLT with tumor micro-
environment, both HTB177 and A549 tumor-bearing mice were
divided into three groups of three mice in each, and either 18F-FDG
(7.4MBq) and 18F-FLT (7.4MBq) or the cocktail of 18F-FDG (7.4MBq)
and 18F-FLT (7.4 MBq) was intravenously injected. All animals
received pimonidazole (2 mg) and BrdU (4 mg) simultaneously with
tracer injection. Animals were killed 1 hour later. Hoechst 33342
(0.5 mg, 0.1 ml; Sigma-Aldrich, St Louis, MO) was given through
the tail vein 1 minute before the killing. Individual intratumoral activ-
ity distributions of 18F-FDG and 18F-fluorothymidine and the activity
distribution by simultaneous cocktail injections of both tracers were
determined by autoradiography and compared with immunohisto-
chemistry visualization of hypoxia by pimonidazole and proliferation
by BrdU from same frozen tumor section.
Noninvasive comparison of intratumoral distribution of 18F-FDG
and 18F-FLT in same mouse was achieved by acquisitions of 14 hours
apart with two subsequent micro-PET scans. Micro-PET scan ob-
tained 1 hour after IV injection of 18F-FLT (7.4 MBq) and BrdU
776 Cocktail 18F-FDG and 18F-FLT PET for Lung Cancer Li et al. Translational Oncology Vol. 6, No. 6, 2013
(4 mg). For the purpose of improving the accuracy of repositioning of
a mouse on subsequent studies, before removing the animal from the
imaging table of the micro-PET scanner (Concorde MicroSystems,
Knoxville, TN), the body contour of the mouse was traced on a
piece of paper previously placed under the animal, and also, the mid-
back of the mouse was marked with permanent ink. Approximately
14 hours later, the samemouse was intravenously injected with 7.4MBq
of 18F-FDG together with the hypoxia marker pimonidazole, and
18F-FDG micro-PET images were obtained 1 hour after the uptake
phase. To improve the exact repositioning of the mouse, we used the
built-in alignment laser, the body contour that was drawn during the
first PET imaging, and the permanent ink cross that was also placed
during the initial PET imaging. A total of five mice was studied, each
bearing one HTB177 subcutaneous xenograft on the left hind leg and
an A549 tumor on the right. After completion of PET scans, animals
were killed, and tumors were frozen for histologic procedures.
Intratumoral distribution of 18F-FDG and 18F-FLT in same patients
was also compared. PET/CT images of the patients were obtained
using a GEDiscovery ST PET/CT scanner (GEHealthcare,Milwaukee
WI), following 6 hours of fasting with blood glucose less than 6 mM.
Whole-body 18F-FDG PET/CT scans were obtained 1 hour after
3.7 MBq/kg IV 18F-FDG administration. Ten hours later, second
PET/CT chest images of each patient were obtained 1 hour after
injection of 3.7 MBq/kg 18F-FLT.
In a separate experiment, animals were intravenously injected with
18F-FLT (7.4 MBq) and allowed to uptake for 1 hour; animals were
then anesthetized and placed and taped on a scanner bed that was
covered with a warm pad for PET scan. Immediately after this pro-
cedure, 18F-FDG (7.4 MBq) was given intravenously to the animal; a
second micro-PET was performed 1 hour later (e.g., approximately
120-130 minutes after the 18F-FLT administration). In this study,
the animal was anesthetized and typed on the PET scanner bed for
the first PET scan and kept the same position throughout the process
of second tracer injection, uptake, and the second PET scan. There-
fore, paired images from two individual PET scans of same animal
were able to accurately select, which avoided any potential misregis-
tration due to animal position changed. A total of three mice were
used, each bearing one HTB177 subcutaneous xenograft on the left
and A549 tumor on the right hind leg. Similar experiments were
conducted in the reversed order of tracer injection in same models
of three mice.
Finally, a mixture of 18F-FDG (7.4 MBq) and 18F-FLT (7.4 MBq)
was coadministrated with pimonidazole (2 mg) and BrdU (4 mg)
through the tail vein. Single PET scan was performed 1 hour later
to detect whole-body and intratumoral activity distribution of the
“cocktail tracers” in three mice. After completion of the imaging and
1 minute before killing the mouse, Hoechst 33342 (0.5 mg) was
injected through the tail vein, and harvested tumors were fixed and
sectioned for autoradiography and immunohistochemical staining.
18F-FLT PET was performed 24 hours earlier.
Radiopharmaceuticals
For preclinical animal studies, both 18F-FDG and 18F-fluoride
were purchased from PETNET Pharmaceuticals Inc facility housed
in University of Louisville Hospital (Louisville, KY). 18F-FLT was
purchased from the radiochemical laboratory of Department of
Radiology Small Animal ImagingCore Facility (University of Louisville)
and synthesized as described previously [19].
For clinical human studies, 18F-fluoride was generated using an
in-house cyclotron; 18F-FDG and 18F-FLT were synthesized auto-
matically with FX-FN conventional modules at Inner Mongolia
Medical University PET/CT facility (Hohhot, China). Both 18F-FDG
and 18F-FLT were pyrogen free and qualified for clinical use, with
radiochemical purity greater than 98%.
Markers of Hypoxia, Proliferation, and Perfusion for
Animal Study
The hypoxia marker pimonidazole hydrochloride (Hypoxyprobe
Inc, Burlington, MA) was dissolved in physiological saline at a con-
centration of 20 mg/ml. The proliferation marker BrdU (Roche
Diagnostics, Indianapolis, IN) was first dissolved in dimethyl-
sulfoxide and further diluted in physiological saline to a final concen-
tration of 20 mg/ml. The blood perfusion marker Hoechst 33342
(Sigma-Aldrich) was dissolved in physiological saline at a concentration
of 5 mg/ml. In all cases, fresh drug solutions were prepared on the day
of animal experiments. These markers were not used for patients in
this report.
PET Imaging for Intratumoral Radioactivity Distribution
All animals were imaged in a prone position using a dedicated
three-dimensional small-animal R4 micro-PET (Concorde Micro-
systems) system. The R4 micro-PET scanner has a transaxial field
of view of 10 cm and an axial field of view of 7.8 cm. The obtained
list-mode data were sorted into two-dimensional histograms by
Fourier rebinning, and the images were reconstructed by an iterative
reconstruction algorithm into a 128 × 128 × 63 (0.72 × 0.72 × 1.3 mm)
matrix. In all animal studies, acquisition time was set to 10 minutes
for each PET scan. Before each PET study, overnight fasted animals
were anesthetized by inhalation of an isoflurane (1.5%)-air mixture.
All image sets for each animal were visually examined using a
rotating (cine) three-dimensional display. The window and level set-
tings were adjusted for best visual intratumoral tracer distribution.
For human studies, a Discovery ST8 PET/CT scanner (GE Health-
care) was used. CT based attenuation correction was applied to all
PET studies.
Digital Autoradiography on Frozen Sections
Following animal killing, autoradiography of the harvested tumor
sections was obtained by placing the tumor sections against the
imaging plate in a film cassette as described previously [10,19,24].
The same plate was used through the experiments; the plate was
exposed to tumor sections for approximately 20 hours and read by
a Cyclone Plus imaging system (PerkinElmer, Inc, Waltham, MA),
which generated digital images with pixel dimensions of 42 × 42 μm.
Visualization of Hypoxia (Pimonidazole), Proliferation (BrdU),
and Perfusion (Hoechst 33342)
Pimonidazole, BrdU, and Hoechst 33342 images of the tumor
specimens were obtained after completion of autoradiography as
described previously [16]. To minimize misalignment of the sections
and registration errors, same tumor sections used for digital autoradio-
graphy were used to obtain these images. Briefly, slides were air dried,
fixed in cold acetone (4°C) for 20 minutes, and incubated with Super-
Block (37515; Pierce Biotechnology, Rockford, IL) at room tempera-
ture for 30 minutes. All three antibodies were applied in SuperBlock.
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Sections were then incubated with fluorescein isothiocyanate–conjugated
antipimonidazole monoclonal antibody (Hypoxyprobe Inc), diluted
1:25, for 1 hour at room temperature. For BrdU staining, same sec-
tions after antipimonidazole antibody and Hoechst 33342 imaging
acquired were treated with 2N HCl for 10 minutes at room temper-
ature, followed by 0.1 M Borax for 10 minutes at room temperature.
Sections were then exposed to Alexa Fluor 594–conjugated anti-BrdU
antibody (1:20 dilution; Molecular Probes, Eugene, OR) for 1 hour at
room temperature.
Immunohistochemical staining images were acquired at ×40 mag-
nification using a Nikon Eclipse E800 fluorescence microscope
(Nikon Americas Inc, Melville, NY) equipped with a motorized stage
(Ludl Electronic Products Ltd, Hawthorne, NY). Hoechst 33342 and
pimonidazole were imaged using blue and green filters, respectively.
BrdU was imaged using a red filter. Hematoxylin and eosin stain of
the tumor sections was imaged by light microscopy. Microscopic
images from same frozen sections were coregistered using Photoshop
7.0 (Adobe, San Jose, CA).
Results
Ex vivo experiments on HTB177 tumor sections using autoradiog-
raphy and immunohistochemistry demonstrated excellent spatial
colocalization of high levels of 18F-FDG activity and pimonidazole-
stained areas of hypoxia. In such areas, there were only few prolifer-
ating cancer cells displaying minimal BrdU binding. 18F-FLT prefer-
entially accumulated in areas of tumors where proliferating cells were
present, demonstrating high degree of BrdU binding and low degree
of pimonidazole retention indicating oxic cells. Stroma and necrotic
zones were also associated with lower 18F-FDG and 18F-FLT activity
Figure 1. Intratumoral accumulation of 18F-FDG, 18F-FLT, and their cocktail and tumor microenvironment components in HTB177
tumors. Tumor-bearing mice were intravenously injected either with 18F-FDG (7.4 MBq) or 18F-FLT (7.4 MBq) or with the mixture of both.
All received pimonidazole (2 mg) and BrdU (4 mg) simultaneously. Animals were killed 1 hour later. Hoechst 33342 (0.5 mg, 0.1 ml) was
given through the tail vein 1 minute before the killing. Overlay imaging of immunohistochemical stains: hypoxia marker pimonidazole
(green), proliferation marker BrdU (red), and perfusion marker Hoechst 33342 (blue). (A) Top panel: 18F-FDG uptake is high in hypoxic
regions (green) as arrow indicated. 18F-FDG accumulation is absent in delineated proliferating tissue where BrdU (red) was positive and
with Hoechst-positive well perfusion regions (arrowhead). Middle panel: 18F-FLT accumulates in proliferative (red) cancer component as
arrowhead indicated, not hypoxic (green) zones (arrow). Bottom panel: Coinjection of 18F-FDG and 18F-FLT (cocktail). Both hypoxic
(green) and proliferative (red) cancer cells associate with high activity. (B) In hypoxic zone, 18F-FLT and 18F-FDG cocktail uptake ratio
relative to that of necrosis is not significantly different from that of 18F-FDG but is significantly higher than that of 18F-FLT. *P < .01 to all
other groups. (C) In proliferation zone, the ratio of 18F-FLT and 18F-FDG cocktail uptake relative to that of necrosis is not significantly different
from that of 18F-FLT but is significantly higher than that of 18F-FDG. *P < .01 to all other groups.
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(Figure 1A). However, after injecting 18F-FLT and 18F-FDG cocktail,
high degree of radioactivity accumulation was noted to associate with
hypoxic (pimonidazole-stained positive) and proliferative (BrdU-
stained positive) cancer cells; the radiotracer activity in stroma and
necrotic zones remained to be low (Figure 1A). In hypoxic zone,
18F-FLT and 18F-FDG cocktail uptake ratio relative to that of necro-
sis was not significantly different from that of 18F-FDG but was sig-
nificantly higher than that of 18F-FLT (Figure 1B). In proliferation
zone, the ratio of 18F-FLT and 18F-FDG cocktail uptake relative to
that of necrosis was not significantly different from that of 18F-FLT
but was significantly higher than 18F-FDG (Figure 1C ). Results were
similar in both HTB177 and A549 xenograft tumor tissue sections.
We compared the intratumoral distribution of each tracer in same
mouse by PET scans performed 14 hours apart (Figure 2A). In five
mice with A549 (right leg) and HTB177 (left leg) NSCLC tumor
xenografts, we demonstrated that intratumoral distribution of 18F-FLT
and 18F-FDG, injected 14 hours apart from each other, displayed dif-
ferent tracer distribution patterns on their PET images. Such differences
were better visualized when three-dimensional rotating (cine) maximum
intensity projection (MIP) images were displayed side by side. A typical
example is shown in Figure 2, B to F , as follows: the distributions of
18F-FLT and 18F-FDG did not fully match to each other in either
HTB177 (left) or A549 (right) NSCLC tumor xenografts. Pimonidazole
and BrdU distribution was also mismatched (Figure 2G ). Such mis-
match patterns were observed when the agents were injected 14 hours
apart or when injected together simultaneously, which indicated that
tumor hypoxia and proliferation were relatively stable at least during
the 14-hour interval.
Such mismatched pattern observed in mice was also demonstrated
in two patients with lung cancer, when their 10-hours-apart 18F-FDG
PET/CT and 18F-FLT PET/CT images of lung tumors were com-
pared to each other. The intratumoral distribution of 18F-FDG and
18F-FLT appeared mismatched, confirming the findings observed
on preclinical mouse studies. A set of representative PET/CT images
of a 61-year-old male patient with NSCLC is presented in Figure 3
displaying a significant intratumoral tracer distribution difference
and mismatch.
Subsequent PET scans were performed following the flow chart
shown in Figure 4A. Coronal PET slices were presented; the initial
18F-FLT image (scan 1) was compared to a combining 18F-FDG and
18F-FLT image (scan 2). There was a clear increase in the fraction of
the tumor showing enhanced uptake of radioactivity in combination
of 18F-FDG and 18F-FLT image than 18F-FLT–alone imaging (Fig-
ure 4, B and C ). The same pattern was seen when given radiophar-
maceuticals in the reverse order (Figure W1). Results were broadly
similar in all the mice we examined.
Intratumoral distributions of the radiotracers were also determined
after simultaneous “cocktail” injection of 18F-FLT and 18F-FDG
PET mixture (Figure 5B ) and compared with the 18F-FLT–only
PET images of the same mouse that were obtained 24 hours earlier
Figure 2. Difference in intratumoral distribution of 18F-FLT and 18F-FDG in same mouse during a 14-hour interval. (A) Schematic of
experimental design. (B) A coronal slice of 18F-FLT PET. (C) The coronal slice of 18F-FDG PET from same level of the mouse. (D) Intra-
tumoral high 18F-FLT regions in HTB177 slice shown in B were contoured. (E) Intratumoral high 18F-FDG regions shown in C were
contoured. (F) Overlay of the contours of high intratumoral radioactivity–accumulated regions: 18F-FLT (red) and 18F-FDG (blue).
(G) Pimonidazole (hypoxia, green) and BrdU (proliferation, red) distribution maintains a mutually exclusive pattern when injected 14 hours
apart in the frozen tumor section. Hoechst 33342 (blue) indicates functional blood perfusion.
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Figure 3. Difference in intratumoral distribution of 18F-FLT and 18F-FDG in a patient. A 61-year-old male with pretreated lung adeno-
carcinoma underwent 18F-FLT PET/CT and 18F-FDG PET/CT scans during 10-hour interval. Apparent difference in intratumoral distribution
between the two radiopharmaceuticals is presented as arrow and arrowhead indicated.
Figure 4. 18F-FLT–alone PET versus the combination of 18F-FLT and 18F-FDG PET on cancer tissue visualization. (A) Schematic of
the experimental design. (B) 18F-FLT coronal PET slices (scan 1), and combination of 18F-FLT and 18F-FDG coronal PET slices (scan 2).
(C) Top: Intratumoral distribution of 18F-FLT in region of interest (ROI) of slice 62 in B (upper panel). Bottom: Intratumoral distribution of
the combination of 18F-FLT and 18F-FDG in ROI of slice 62 (B, lower panel) maps more higher-radioactivity tissue, indicating better viable
cancer tissue visualization.
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(Figure 5A). The intratumoral distribution of both radiotracers
together clearly showed an increase in the fraction or volume of
tumor with increased PET tracers compared to PET images obtained
with 18F-FLT injections alone. Autoradiography of the tumors ob-
tained from the mouse (Figure 5C ) revealed that intratumoral radio-
activity accumulation was associated with viable cancer cells, which
were either hypoxic (pimonidazole-stained positive) or proliferative
(BrdU-stained positive) (Figure 5D); stroma and necrotic zones asso-
ciated with lower radioactivity (Figure 5, C and E ).
Discussion
Human NSCLC and most solid cancers have a very heterogeneous
microenvironment, being composed of viable cancer cells, non-
cancerous stroma, and necrotic zones. Viable cancer cells are either
minimally proliferative and hypoxic cancer cells or oxic and highly
proliferative cancer cells, and proliferation and hypoxia are generally
exclusive [16–19,24–27]. Therefore, an ideal PET tracer must bind
indiscriminately to all viable cancer cells regardless of their status of
oxygenation or proliferation.
PET imaging with 18F-FDG and 18F-FLT has been widely used in
the management of cancer. However, neither of them has fully dem-
onstrated conclusive superiority of one to another [1–12,28–32].
This was presumably due to the highly spatial and temporal hetero-
geneous nature of the tumor microenvironment [33–35] and the dif-
ferences in uptake mechanisms of 18F-FDG and 18F-FLT. 18F-FDG
is preferentially taken up by hypoxic cancer cells [8–10,19–21]. In
contrast, 18F-FLT accumulates predominantly in proliferative cancer
cells and is unlikely taken up by hypoxic cells, as they are minimally
proliferative [19]. Therefore, neither 18F-FDG nor 18F-FLT alone is
perfect for a complete identification of viable cancer cells in solid
tumors containing complex tumor microenvironment.
In a previous ex vivo study, we demonstrated that there is a mis-
matched intratumoral activity distribution pattern of 18F-FDG and
18F-FLT (exclusive to each other) [19], which was reconfirmed in
this study as well (Figure 1).
Current study noninvasively demonstrated the exclusive pattern
distribution mismatch of 18F-FDG and 18F-FLT in mouse model
of NSCLC when injected into same mice sequentially 10 to 14 hours
apart from each other (Figure 2) and in two patients with recent
diagnosis of pretreated NSCLC as well (Figure 3). Thus, although
preliminary, these findings suggest that the exclusive pattern of intra-
tumoral distribution of 18F-FDG and 18F-FLT can be noninvasively
imaged in mice and humans with NSCLC.
Figure 5. The power of 18F-FLT and 18F-FDG cocktail PET on viable cancer tissue identification. 18F-FLT PET (A) was conducted 24 hours
before 18F-FLT and 18F-FDG cocktail PET (B) in same mouse is presented. Apparent difference in whole-body radioactivity distribution
from two scans is noted. Followed the animal killed, tumors were removed, frozen, and sectioned. Histologic findings from same frozen
section of A549 tumor on the right thigh were presented. (C) Digital autoradiography of intratumoral distribution of cocktail. Both hypoxic
and proliferative cancer cells associate with high radioactivity; “cold” areas on the autoradiograph correspond to either necrotic tissue (N)
or stroma (S). (D) Overlay imaging of immunohistochemical stains: hypoxia marker pimonidazole (green), proliferation marker BrdU (red),
and perfusion marker Hoechst 33342 (blue). (E) Hematoxylin and eosin stain is provided as reference.
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The 10- to 14-hour time interval, which is slightly over five to
seven half-lives decay for F-18, was chosen to minimize the residual
radioactivity effect remaining from the first injection into the second
imaging (Figures 2 and 3). Because the distribution pattern of BrdU
coinjected with 18F-FLT and pimonidazole coinjected with 18F-FDG
was still mutually exclusive, the tumor microenvironment is probably
mostly stable during this period. The possibility of a change in the
tumor microenvironment during this period then is not a major con-
cern (Figure 2G ). Thus, the demonstrated mismatch pattern of these
radiotracers on PET images was valid and reflected the real relation-
ship of 18F-FDG and 18F-FLT uptake in vivo and not the consequence
of significant spatial change in the intratumoral microenvironment.
Although there is a predominant mismatch in spatial distribution
of 18F-FDG and 18F-FLT in NSCLC tumors both in mouse (Fig-
ure 2) and in human (Figure 3), a detailed evaluation reveals some
activity overlaps between 18F-FDG– and 18F-FLT–positive areas.
One explanation is that this could be due to a possible micro-
environmental heterogeneity that is below the resolution of used
current PET technology. However, presence of a slight change in
tumor microenvironment in some portion of the tumor cannot be
totally excluded.
This preliminary study suggests that the simultaneous, combined
18F-FDG and 18F-FLT PET imaging identifies more viable cancer
tissue than when either tracer is injected individually (Figures 1,
4, and W1). Autoradiography and histologic, immunohistochemical
assays have proved that minimally proliferative/hypoxic cancer cells
as well as highly proliferative/oxic cells accumulated high levels of
radioactivity when 18F-FDG and 18F-FLT were administered simul-
taneously as a cocktail (Figure 1) or in a sequence one after another
with a couple of hours apart (data not shown).
The accumulation of 18F-FDG and 18F-FLT cocktail might be
independent of the oxygenation or proliferation status of cancer cells.
Consequently, dual-tracer PET is more capable of better identifying
the viable portion of the tumor mass from tumor necrosis and/
or stroma; neither 18F-FDG nor 18F-FLT alone has the ability to do so.
Tumor microenvironment in terms of proliferation, glucose metab-
olism, and hypoxia has temporal heterogeneity and is unstable.
Ljungkvist et al. reported that hypoxic human head-neck cancer
cells growing in mice had a rapid turnover rate [36]. Nehmeh et al.
found significant difference in spatial distribution of hypoxia tracer
18F-misonidazole in the same patients with head and neck cancer
when repeat imaging was done over a 3-day interval [37]. Pilot PET
studies have indicated that change in intratumoral distribution of
18F-FLT, 18F-FDG, and 18F-misonidazole occurred in as short as
∼48-hour interval in untreated animal model of lung cancer [35].
Furthermore, changes in intratumoral 18F-FDG distribution in patients
with pretreated solid tumors occurring within a few days interval
have been reported [34,35]. Accordingly, solid tumors are continuously
remodeling, and hypoxic and proliferating cell components are dynam-
ically changing in untreated tumors. Efficient anticancer therapy might
also result in a more dramatic change in the microenvironment of a
solid tumor. Therefore, 18F-FLT PET or 18F-FDG PET in some cases
may not accurately identify the precise volume of the viable portion of a
tumor to reflect the true effect of the anticancer therapy. However, the
combination of 18F-FDG and 18F-FLT PET might be more capable of
accurately identifying the true extent of the viable cancer cells, which
would result in a better-managed anticancer therapy.
In this proof-of-concept study, two individually well-studied PET
radiotracers are proposed to be used in a combination, as a cocktail
mixture of 18F-FDG and 18F-FLT, which might be considered as a
novel tracer. Although the drug safety may not be an issue for the use
of the combination of 18F-FDG and 18F-FLT, burden of the radia-
tion dose issue of the combination may need to be further considered
and/or investigated. Recently, Kadrmas and colleagues have reported
the technical feasibility of dual-tracer 18F-FDG and 18F-FLT on tumor
characterization with a single PET scan [38]. We know that, at least in
NSCLC experimental models, tumors generally have lower 18F-FLT
uptake than 18F-FDG; the maximal intratumoral uptake of 18F-FLT
is around 30% of maximal 18F-FDG uptake [19]. This may be due
to the fact that only <∼30% of cancer cells in the nonhypoxic zones
was proliferative and accumulated 18F-FLT, whereas all cancer cells
in hypoxic zones were presumably able to accumulate 18F-FDG. It is
also recognized that the cell proliferation rate may differ from one
type of cancer to another; therefore, the “cocktail” mixture containing
18F-FDG and 18F-FLT probably needs to have a ratio in a range of
approximately 1:1 to 1:3 to produce better, accurate PET images, which
may be taken as a reference proposal preparing the “cocktail” for future
investigations. Thus, before this new imaging strategy is to be accepted
for its routine clinical use, in addition to the need for further search of
optimization of radiation dose, the mixture ratio of these tracers and
the clinical significance (outcome) of their use as a cocktail in the
management of cancer therapy needs to be further investigated.
Conclusion
The combination of 18F-FDG and 18F-FLT with single PET imaging
would give a more accurate representation of viable tumor tissue vol-
ume than a PET image obtained with either tracer alone. “Cocktail”
PET imaging might be a novel imaging strategy for cancer and pro-
duces images that are less dependent on oxygenation and/or prolifer-
ative status of cancer cells. The simultaneous combination use of dual
tracers as a “cocktail” is a promising PET imaging strategy in cancer
management of patients. Its potential clinical significance needs to be
further studied.
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Figure W1. 18F-FDG versus the combination of 18F-fluorothymidine
and 18F-FDG on cancer tissue visualization. (A) Schematic of the
experimental design. (B) Left top: Coronal 18F-FDG PET slice (scan 1).
Left bottom: Enlarged view of the ROI of the top imaging. Right top:
Coronal PET slice of the combination of 18F-fluorothymidine and
18F-FDG (scan 2) from same level shown in B (left). Right bottom:
Intratumoral distribution of the combination of 18F-fluorothymidine
and 18F-FDG in ROI of the top imaging.
